Q-omics provides the consensus-scored TSSK4 profile across patient tissues and cancer cell-line models. TSSK4 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TSSK4 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TSSK4 RNA expression shows 21,018 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where TSSK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSSK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSSK4 survival associations across molecular data types. TSSK4 RNA expression shows survival associations in the most cancer types (30), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSSK4 RNA expression–survival associations across cancer types. High TSSK4 expression shows unfavorable associations in COAD and ACC, but favorable associations in HNSC, SKCM, BRCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TSSK4 RNA expression.
This table summarizes TSSK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TSSK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSSK4 shows lower tumor expression in THCA, BRCA and UCEC and higher tumor expression in LIHC, CHOL and HNSC. The THCA box plot shows higher TSSK4 RNA expression in normal versus tumor tissue (log2 FC = −0.809, t-test p < 0.001).
This table shows molecular features associated with TSSK4 in patient tissues and cancer cell lines. In patient samples, TSSK4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSSK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
